...Tomohiro Kameda; Yoshimasa Kondo; Yasuko Fukataki; Shiro Hinotsu; Tetsuya Fujimura; Tatsuya Takayama Introduction: The aim of the study was to examine whether disinfection of bacillus Calmette-Guerin-containing urine with etaprocohol® (ethanol 76.9–81.4 vol % and isopropanol as an additive...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2021 Bladder cancer Electromotive drug administration Bacillus Calmette-Guérin Intravesical treatment Non-muscle-invasive bladder cancer...

... cancer. J Urol . 2008 Apr; 179(4): 1302–5. 8. Heiner JG, Terris MK. Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guérin therapy. Urol Oncol . 2008 Mar-Apr; 26(2): 137–40. 9. Izquierdo L, Peri L, Leon P, Ramírez-Backhaus M, Manning T, Alcaraz...

... receiving Bacillus Calmette-Guerin (BCG) immunotherapy. Material and Methods: This retrospective study enrolled 491 patients with bladder cancer receiving BCG intravesical therapy between 1998 and 2016. All patients were followed up for at least 12 months and received at least 7 BCG instillations...

...Wojciech Krajewski; Michal Matuszewski; Sławomir Poletajew; Jędrzej Grzegrzółka; Romuald Zdrojowy; Anna Kołodziej Purpose: To evaluate if there are differences in toxicity and efficacy between different Bacillus Calmette-Guerin (BCG) stains used for intravesical immunotherapy in patients with non...

... cancer from January 1999 to January 2014. Of these, 64 patients were diagnosed with CIS and were treated with at least 6 cycles of Bacillus Calmette-Guérin (BCG). We accessed variables including patient age, sex, initial presenting symptoms, smoking history, P-CIS descriptions, urine cytology...

...Sławomir Poletajew; Piotr Zapała; Piotr Radziszewski Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy in bladder cancer patients with asymptomatic bacteriuria (ABU) remains a matter of debate. The aim of this systematic review was to present available evidence on the safety and efficacy...

...Vladimir Novotny; Michael Froehner; Johanna Ollig; Rainer Koch; Stefan Zastrow; Manfred P. Wirth Purpose: To evaluate the impact of adjuvant intravesical bacillus Calmette-Guérin (BCG) treatment in patients with high-grade transitional cell carcinoma of bladder. Patients and Methods: A total of 207...

...Sebastian L. Hofbauer; Shahrokh F. Shariat; Daher C. Chade; Alvaro S. Sarkis; Leopoldo A. Ribeiro-Filho; Willian C. Nahas; Tobias Klatte Background: Bacillus Calmette-Guerin (BCG) is the standard of care for adjuvant intravesical instillation therapy for intermediate- and high-risk non-muscle...

... in a homogeneous series of patients with non-muscle-invasive bladder cancer (NMIBC) treated with Bacillus Calmette-Guérin (BCG). Patients and Methods: 192 intermediate- and high-risk NMIBC cases were enrolled. The variables in study were age, stage, grade, focality, tumour size, presence of associated carcinoma...

...Luís Lima; Joana Silva; Teresina Amaro; António Morais; Carlos Lopes; Rui Medeiros; Paula A. Videira; Lúcio Santos Introduction: This study evaluates the influence of clinicopathological characteristics, bacillus Calmette-Guérin (BCG) therapeutic schedule [maintenance (mBCG) or induction (iBCG...

...Massimo Porena; Michele Del Zingaro; Massimo Lazzeri; Luigi Mearini; Antonella Giannantoni; Vittorio Bini; Elisabetta Costantini Objective: To evaluate the safety, tolerability and efficacy of adjuvant intravesical gemcitabine versus bacillus Calmette-Guérin (BCG) in the treatment of high-risk...

...Atsushi Sasaki; Seiji Kudoh; Kazuyuki Mori; Nobuyoshi Takahashi; Tadashi Suzuki Because we hypothesized that cell death when bacillus Calmette-Guérin (BCG) was instillated was correlated with apoptosis, cultured urinary bladder carcinoma cells were treated with BCG and examined whether they showed...

...Shinichi Ikemoto; Masato Kamizuru; Seiji Wada; Shoichi Nishio; Taketoshi Kishimoto; Masanobu Maekawa We investigated the effect of combination therapy with interleukin 2 (IL-2) and Bacillus Calmette-Guérin (BCG) on C3H/HeN mice implanted with mouse bladder tumor cells (MBT2). MBT2-bearing mice were...

...Kemal Sarica; Sümer Baltaci; YaÈ™ar Bedük; Okan Süzer; Sahir Kiliç; Ziya Müftüoǧ;lu; Orhan Göǧ;üs Despite its marked effectiveness in the prevention of tumor recurrences, a great deal of information on the mode of action of Bacillus Calmette-Guérin (BCG) as an antitumor therapy modality is still...

...J.A. Witjes; M.P.H. Fransen; A.P.M. van der Meijden; W.H. Doesburg; F.M.J. Debruyne To study maintenance Bacillus Calmette-Guérin (BCG) therapy we treated 49 patients with recurrent superficial bladder cancer pTa and/or carcinoma in situ, failing previous intravesical chemotherapy. They received 20...

...Ali Erol; Suat Özgür; Murat Basąr; Selahattin Çetin The efficacy and side effects of the prophylactic intravesical bacillus Calmette-Guérin and epirubicin combination therapy were evaluated in 14 patients who underwent transurethral resection for Ta–T1 superficial bladder cancer. Therapy...

...J.A. Witjes; A.P.M. v.d. Meijden; F.M.J. Debruyne Since 1976 superficial bladder cancer is treated with intravesical instillations of Bacillus Calmette-Guérin (BCG). The results with BCG are superior to other intravesical chemotherapeutics, both in superficial tumors and carcinoma in situ. BCG...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Natural killer cells Prostatic carcinoma Adjuvant immunotherapy Hormone therapy Bacillus Calmette-Guérin Original Papers Urol. int. 39: 321...

...Masatoshi Eto; Hirofumi Koga; Hideya Noma; Akito Yamaguchi; Yasunobu Yoshikai; Seiji Naito Objective: Intravesical immunotherapy with bacillus Calmette-Guérin (BCG) remains the most efficient modality for the treatment of carcinoma in situ and prevention of recurrences of Ta and T1 bladder tumors...